CAM2100

CAM2100 (also identified by the study codes HS-24-802 and HS-25-802) is an investigational, long-acting subcutaneous depot formulation of the GLP-1 receptor agonist semaglutide, developed by Camurus using its proprietary FluidCrystal technology. The product is designed for monthly administration, aiming to provide a more convenient dosing schedule and improved adherence for patients with obesity and type 2 diabetes compared to existing weekly formulations. CAM2100 entered clinical development in late 2024 with a first-in-human Phase 1 trial conducted in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetic profile. While the active ingredient was initially undisclosed in official trial summaries, financial analyst reports and patent filings have identified the asset as a long-acting semaglutide formulation.

Other names

semaglutide FluidCrystal